Divi's Laboratories reported consolidated revenue of ₹9,712 Cr for FY25, up 18.7% YoY, with PBT and PAT rising to ₹2,916 Cr and ₹2,191 Cr respectively.

Standalone revenue stood at ₹9,550 Cr with PAT of ₹2,209 Cr.

Commercial operations began at Unit III greenfield project near Kakinada, capitalizing ₹755 Cr.

The board proposed a final dividend of ₹30 per share (1500%). Leadership change noted as CFO L. Kishore Babu retires, succeeded by Venkatesa Perumallu Pasumarthy.